In the previous study [14], cystic and fibrotic liver and kidney disease progression was significantly reduced by a full PPAR-γ agonist in PCK rats without angiotensin II receptor blockade, demonstrating that both liver and kidney are sensitive to the beneficial effects of PPAR-γ agonist. The gene discussed is PPARG; the disease is kidney disorder.